Pericarditis. Causes, Mechanisms of Development, Variants of Course and Therapeutic Approaches in Modern Conditions DOI Open Access
И. Т. Муркамилов, К. А. Айтбаев,

Z. Raimzhanov

et al.

Bulletin of Science and Practice, Journal Year: 2024, Volume and Issue: 10(3), P. 246 - 286

Published: March 15, 2024

Under physiological conditions, the pericardial cavity contains serous fluid (15-50 ml), which belongs to plasma ultrafiltrate and is visualized during echocardiography only in systole. The thickness of pericardium an adult averages 2 mm (1-3 mm). Inflammatory lesions with or without effusion into its can act as independent disease, a secondary manifestation another pathological condition. Pericarditis infectious (14-16%) non-infectious (15-20%) nature, primary secondary, acute, chronic recurrent are commonly distinguished. prevalence acute idiopathic pericarditis 27.7 per 100,000 population 5.4-8.1 population, respectively. Currently, polygenic autoinflammatory diseases, where important role initiation pathologic process inflammatory cytokine — interleukin-1 (β α). most characteristic manifestations chest pain, dyspnea fever. article summarizes main aspects etiology, clinical manifestations, diagnosis therapy pericarditis, including peculiarities treatment taking account specific conditions. A case demonstrated recurrence, was characterized by rapid progression heart failure symptoms, well systemic (anemia, hypercytokinemia, marked muscle weakness). results allowed identify presence effusion. Steroid non-steroidal anti-inflammatory, anticoagulant antibacterial led disappearance normalization activity markers serum. However, dynamics observation attempt suspend glucocorticoid again accumulation pericardium, required continuation steroidal anti-inflammatory drugs.

Language: Английский

Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis DOI

Jared M. Feldman,

William H. Frishman, Wilbert S. Aronow

et al.

Cardiology in Review, Journal Year: 2024, Volume and Issue: unknown

Published: May 2, 2024

Anticytokine biologics are a promising anti-inflammatory therapy for recurrent pericarditis. Several studies have proved the efficacy and safety of interleukin-1 (IL-1) inhibitors, such as anakinra rilonacept in patients with Treatment goflikicept recent phase 2 3 trial significantly reduced pericarditis recurrence rate compared both placebo allowed withdrawal standard-of-care therapy. Patients idiopathic (IRP) achieved remission within first 14 days In inhibition alpha beta (phase trap pericarditis), led to lower risk than (hazard ratio, 0.04; P < 0.001) rapid resolution episodes. However, 74% group demonstrated recurrence, 7% group. The was by AIRTRIP (anakinra-treatment pericarditis) trial, which showed reduction incidence versus placebo-treated (18.2% vs 90%). recurrences, mean time flare 28.4 76.5 IL-1 inhibitors require further research potential decrease use first-line drug regimens that not tolerated specific patient groups.

Language: Английский

Citations

1
Pericarditis. Causes, Mechanisms of Development, Variants of Course and Therapeutic Approaches in Modern Conditions DOI Open Access
И. Т. Муркамилов, К. А. Айтбаев,

Z. Raimzhanov

et al.

Bulletin of Science and Practice, Journal Year: 2024, Volume and Issue: 10(3), P. 246 - 286

Published: March 15, 2024

Under physiological conditions, the pericardial cavity contains serous fluid (15-50 ml), which belongs to plasma ultrafiltrate and is visualized during echocardiography only in systole. The thickness of pericardium an adult averages 2 mm (1-3 mm). Inflammatory lesions with or without effusion into its can act as independent disease, a secondary manifestation another pathological condition. Pericarditis infectious (14-16%) non-infectious (15-20%) nature, primary secondary, acute, chronic recurrent are commonly distinguished. prevalence acute idiopathic pericarditis 27.7 per 100,000 population 5.4-8.1 population, respectively. Currently, polygenic autoinflammatory diseases, where important role initiation pathologic process inflammatory cytokine — interleukin-1 (β α). most characteristic manifestations chest pain, dyspnea fever. article summarizes main aspects etiology, clinical manifestations, diagnosis therapy pericarditis, including peculiarities treatment taking account specific conditions. A case demonstrated recurrence, was characterized by rapid progression heart failure symptoms, well systemic (anemia, hypercytokinemia, marked muscle weakness). results allowed identify presence effusion. Steroid non-steroidal anti-inflammatory, anticoagulant antibacterial led disappearance normalization activity markers serum. However, dynamics observation attempt suspend glucocorticoid again accumulation pericardium, required continuation steroidal anti-inflammatory drugs.

Language: Английский

Citations

0